Clinical Trial Search

Primary: Percentage of Participants Achieving a Genital Vitiligo Noticeability Scale (VNS) of "4 - A Lot Less Noticeable" or "5 - No Longer Noticeable" at Week 48 — 27.0…

Primary: Number of Participants With Treatment-Emergent Adverse Events and Treatment Emergent Serious Adverse Events — 51; 63; 62; 21 Participants

Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants

Primary: Change in Proliferative Index (Ki67 Expression) — -14.5; -10.0 Difference from baseline (%) — p=0.002

Primary: Percentage of Participants Achieving MCID (Minimal Clinically Important Difference) on the Smell Identification Test (SIT) — 66.70; 28.57; 66.70; 42.86 percentage of…

Primary: Pain Score During the Tampon Test — 4.37; 3.75; 4.04; 4.36 score on a scale — p=0.3630

Primary: Progression Free Survival — 49.2; 46.9 percentage

Primary: Solicited Local Adverse Events (AEs) — 0; 0; 0; 0 events

Primary: Change in the PaO2/FiO2* Ratio From Baseline to Day 7 of Treatment Administration — 83.3; 57.6 mmHg/mmHg

Primary: Measure Ki67 Index in Highly Hormone-dependent Breast Cancers vs. Those That Are Not — 7; 6; 40 Participants

Primary: Change From Baseline Neurocognitive Function at 10 Weeks - Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall Standardized Score — 0.09; -0.40 Change in…

Primary: Volumetric Response Rate — 0; 9 Participants

Primary: Polymerase Chain Reaction (PCR) Corrected Adequate Clinical and Parasitological Response (ACPR) — 96.43; 96.67 Percentage of participants

Primary: Change in BMI — 0.67; 1.34; 1.8 kg/m^2

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 100; 83.3; 100; 100 percentage of participants